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INTRODUCTION
Pancreatic cancer is one of the leading causes of cancer death 
worldwide. Despite recent advances in therapy, overall sur-
vival (OS) is less than 6 months, and 5-year survival rates for 
unresectable pancreatic cancer patients are very low.1,2 Al-
though gemcitabine was originally regarded as the standard 
chemotherapy agent for advanced pancreatic cancer, any 
benefit was marginal, with an objective response rate of only 
5% and a median survival rate of 5.7 months.3 Throughout the 
last 20 years, a number of clinical trials with various combina-
tions of anti-cancer drugs have been performed. Combina-
tion chemotherapy with folinic acid, fluorouracil, irinotecan, 
and oxaliplatin (FOLFIRINOX) and gemcitabine/nab-pacli-
taxel have shown a remarkable improvement in survival ben-
efits for advanced metastatic pancreatic cancer.4,5 However, 
the OS for both regimens is still less than 1 year, and they can-
not be prescribed to all patients with unresectable pancreatic 
cancer, due to their relatively severe toxicity profiles.
Owing to increased information on the molecular changes 
in cancer, cell-specific anti-cancer targeted agents have been 
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introduced into clinical practice. This shift in the treatment 
paradigm is focused on magnifying the anti-tumor effects while 
minimizing off-target adverse effects, which are the most 
common concern in patient management. There have been 
several clinical trials to assess the benefits of targeted agents 
including erlotinib, bevacizumab, and cetuximab for pancre-
atic cancer. To date, only erlotinib has been accepted as a stan-
dard drug when combined with gemcitabine.6 However, there 
are several issues with using gemcitabine-erlotinib combina-
tion chemotherapy for advanced pancreatic cancer, the most 
important being that there is no predictive factor for response 
to these drugs. In lung cancer, there are several well-known ge-
netic predictive factors for response to tyrosine kinase inhibi-
tors.7,8 Thus far, most studies have concentrated on the relation-
ship between genetic differences and response to erlotinib. 
However, it is also necessary to examine the clinical profiles of 
advanced pancreatic cancer patients, as they usually have co-
existing diseases or conditions that require medications such 
as metformin or statins.9 In particular, statins have been eval-
uated for their potential anti-tumor effects. Recently, Nielsen, 
et al.10 reported that statin use in cancer patients is associated 
with reduced cancer-related mortality in 13 cancer types. Fur-
thermore, several preclinical studies have suggested that statins 
have potential anti-cancer properties, including inhibition of 
cell proliferation, resulting in inhibition of tumor growth and 
angiogenesis.11-14 Other studies have demonstrated that the anti-
cancer effect is due to statin-induced posttranscriptional modi-
fication of Ras and RhoA.15-17
In this study, we attempted to determine the clinical factors 
that predict response to gemcitabine-erlotinib combination 
chemotherapy in advanced pancreatic cancer patients. We fo-
cused on the effect of concomitant statins on the oncologic 




This study included patients with unresectable or recurrent 
pancreatic cancer who received gemcitabine plus erlotinib as 
first-line chemotherapy at Severance Hospital (Seoul, Korea), 
between November 2006 and January 2014. All patients were 
histologically diagnosed with pancreatic adenocarcinoma 
and underwent dynamic computed tomography (CT) of the 
abdomen and pelvis. The tumors were classified as recurrent, 
locally advanced (including stage III), and advanced pancreatic 
cancer (including stage IV) using the American Joint Commit-
tee on Cancer (7th edition) guidelines. Patients were excluded 
if they had other malignancies, were unable to determine treat-
ment response, had serum creatinine or total bilirubin levels 
>1.5×upper limit of normal (ULN), or had cardiomegaly on a 
chest radiograph.
Measurement of clinical factors
The clinical factors examined in this study were sex; age; his-
tory of diabetes mellitus, smoking, or chronic pancreatitis; type 
of operation; location or size of tumor; involvement of region-
al lymph nodes; number of metastatic organs; location of me-
tastasis; locally advanced stage; involvement of major vessels; 
laboratory parameters including carbohydrate antigen (CA) 
19-9, carcinoembryonic antigen (CEA), and bilirubin levels; 
and history of statin or aspirin treatment. Statins and aspirin 
could have been taken before or simultaneously with chemo-
therapy. Levels of CA 19-9, CEA, and bilirubin were evaluated 
before the first round of chemotherapy.
Treatment and assessment of therapeutic efficacy
Erlotinib was administered at a dose of 100 mg daily without in-
terruption. Gemcitabine (1000 mg/m2) was administered by a 
30-minute intravenous infusion on days 1, 8, and 15. The cycles 
were repeated every 28 days, provided that the absolute neu-
trophil count was >1500/μL, the platelet count was >100000/μL, 
bilirubin was <2×ULN, and serum creatinine was <1.5×ULN. 
Treatment was discontinued in cases of progressive disease, 
unacceptable adverse events, or withdrawal of patient consent. 
Tumor responses were assessed via CT every 8 weeks (two cy-
cles) subject to the patient’s condition or earlier in those with 
suspected progression based on the Response Evaluation Cri-
teria in Solid Tumors.
Analysis of oncologic outcomes
The primary goal was to determine any clinical factors that in-
fluenced the response to gemcitabine-erlotinib chemotherapy. 
Therefore, we defined “long-term response” as occurring when 
gemcitabine-erlotinib chemotherapy was proven to show a 
tumor stabilization effect after six cycles of chemotherapy. 
The parameters for evaluating the tumor stabilization effect in-
cluded complete response (CR), partial response (PR), and sta-
ble disease (SD) rates. In addition, we analyzed progression-free 
survival (PFS) and OS rates.
Statin exposure assessment
We reviewed the drug name, the cumulative duration of statin 
use, and the cumulative dose of statin intake. Statin users were 
defined as patients who received statin medications for at least 
30 days. The statins prescribed during the study period were 
atorvastatin, rosuvastatin, simvastatin, and pitavastatin. The 
brand names of statins used in this study were as follows: sim-
vastatin (Cholesnone, Simvastar, Vytorin); atorvastatin (Atorva, 
LipiLOU, Lipitor); rosuvastatin (Crestor, Vivacor); pitavastatin 
(Livalo).
The cumulative dose was standardized for different statins 
using the defined daily doses (DDDs) recommended by the 
World Health Organization.10,18 The DDD for the 30 mg formu-
lation of simvastatin was used as a reference, and the DDDs for 
the other statins were used to convert each statin dose to a dose 
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equivalent to 30 mg of simvastatin.
Statistical analysis
The clinical factors associated with response rates were inves-
tigated by using multivariable regression modeling. The influ-
ence of potential prognostic factors on OS and PFS was assessed 
by using the Cox hazards regression model to estimate the 
hazard ratio (HR). Values of p<0.05 were considered to be sta-
tistically significant. Statistical analysis was performed using 
SPSS software, version 21.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Patient characteristics
This study included 180 patients with unresectable pancreatic 
cancer who received at least 2 cycles of gemcitabine-erlotinib 
combination therapy as first-line palliative chemotherapy be-
tween November 2006 and January 2014. The characteristics 
of the patients are shown in Table 1. The median age was 65 
years. Twenty-four of 180 patients (13.3%) had locally advanced 
disease, and 156 (86.7%) had metastatic disease or recurrent 
disease after curative resection. The metastasis had spread to 
at least two organs in 61 patients (33.9%) and to one organ in 
95 (52.8%). The liver was the most frequently metastatic site in 
122 patients (67.8%), and carcinomatosis occurred in 39 (21.7%). 
Pretreatment CA 19-9 levels >1000 U/mL were detected in 87 
patients (50.3%), and the median level was 1020 U/mL. Pre-
treatment CEA levels >4.5 ng/mL were measured in 84 patients 
(50.9%), and the median level was 4.67 ng/mL. The median 
number of gemcitabine-erlotinib combination chemotherapy 
cycles was four.
An objective response after two cycles of chemotherapy was 
observed in 40 patients (0 CR and 40 PR), resulting in a respo-







Median (range) 65.0 (18–81)
Past history
Chronic pancreatitis history 6 3.3










Distal pancreatectomy 5 2.8
PPPD 10 5.6
Tumor size (mm)










Liver metastasis 122 67.8
Lung metastasis 31 17.2
Carcinomatosis 39 21.7
Bone metastasis 4 2.2
LN metastasis
Regional LN 109 60.6








Median (IQR) 4.67 (2.4–13.1)
Bilirubin (mg/dL)
Median (range) 0.6 (0.1–6.8)
Number of cycles
Median (range) 4 (2–29)
Table 1. Baseline Patient Characteristics (Continued)
Characteristic Number Percent




Response rate 40 22.2
Disease control rate 114 63.3
Long-term response* 54 30
Survival (months)
PFS, median (95% CI) 3.9 (1.7–12.9)
OS, median (95% CI) 8.1 (3.0–20.5)
Death 150 83.3
LN, lymph node; IQR, interquartile range (25–75%); CA, carbohydrate antigen; 
CEA, carcinoembryonic antigen; CR, complete response; PR, partial response; 
SD, stable disease; PFS, progression-free survival; OS, overall survival; CI, 
confidence interval; PPPD, pylorus-preserving pancreaticoduodenectomy.
*When gemcitabine-erlotinib chemotherapy was proven to show a tumor 
stabilization effect (CR, PR, or SD) by six cycles of chemotherapy.
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nse rate of 22.2%. The disease control rate was 63.3% after two 
cycles of chemotherapy. A “long-term response,” which was 
defined as having achieved CR, PR, or SD after six cycles of 
chemotherapy, was observed in 54 patients (30%). The medi-
an PFS and OS were 3.9 and 8.1 months, respectively. At the 
time of final data analysis, 162 of 180 patients (90%) had died.
Among all 180 patients, 17 received statin. Atorvastatin was 
most commonly prescribed (n=8, 47.1%), followed by rosuv-
astatin (n=6, 35.3%), simvastatin (n=2, 11.8%), and pitavastatin 
(n=1, 5.8%), as described in Supplementary Table 1 (only on-
line). Among the patients that received statins during the 
study period, the median duration of use was 182 days.
Statistical analysis to determine response factors after 
two cycles of chemotherapy
Univariate analyses of the clinical characteristics indicated that 
six different factors were associated with response after two 
cycles of chemotherapy (Table 2). The following clinical fac-
tors showed statistical significance: pancreatic tail cancer 
[odds ratio (OR), 0.31; 95% confidence interval (CI), 0.12–0.78; 
p=0.013], locally advanced stage (OR, 3.71; 95% CI, 1.5–9.1; 
p=0.004), one metastatic organ (OR, 0.36; 95% CI, 0.14–0.91; 
p=0.03), two or more metastatic organs (OR, 0.15; 95% CI, 
0.05–0.47; p=0.001), carcinomatosis (OR, 0.15; 95% CI, 0.05–
0.47; p=0.01), and a history of statin treatment (OR, 4.79; 95% 
CI, 1.71–13.40; p=0.003).
In the multivariate logistic regression model, which includ-
ed six statistically significant clinical factors from the univari-
ate model, three factors showed independent statistical sig-
nificance (Table 2). The presence of one metastatic organ (OR, 
0.30; 95% CI, 0.11–0.81; p=0.017) and carcinomatosis (OR, 0.17; 
95% CI, 0.02–1.00; p=0.05) were unfavorable factors for re-
sponse. A history of statin treatment was a favorable factor for 
response after two cycles of chemotherapy (OR, 4.69; 95% CI, 
1.41–15.6; p=0.012).
Table 2. Response Factor Analysis
Clinical factors
Response factors* at two cycles of chemotherapy Long-term response factors†
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
OR 95% CI OR 95% CI p value OR 95% CI OR 95% CI p value
Tumor size & location
Tumor size 0.87 0.68–1.11 0.83 0.67–1.04
Head 1.44 0.71–2.92 1.25 0.66–2.39
Body 1.8 0.85–3.79 1.14 0.56–2.30
Tail 0.31 0.12–0.78 0.46 0.15–1.39 0.17 0.67 0.33–1.37
Number of metastatic organs
0 (locally advanced) 3.71 1.50–9.10 3.25 1.23–8.56 0.017 2.71 1.13–6.51 1.61 0.54–4.82 0.392
1 0.36 0.14–0.91 0.3 0.11–0.81 0.017 0.41 0.16–1.04
≥2 0.15 0.05–0.47 1.15 0.37–3.61 0.79 0.29 0.11–0.80
Site of metastasis
Liver 0.56 0.27–1.16 0.46 0.24–0.89 0.58 0.24–1.38 0.223
Lung 0.81 0.31–2.14 0.5 0.19–1.31
Carcinomatosis 0.15 0.03–0.64 0.17 0.02–1.00 0.05 0.76 0.34–1.69
Bone 1.17 0.11–11.57 2.38 0.33–17.38
LN metastasis
Regional LN 1.47 0.69–3.08 1.03 0.54–1.99
Distant LN 1.18 0.36–3.89 0.52 0.18–1.46
Lab parameters
CA 19-9 <1000 1.2 0.58–2.45 1.42 0.74–2.72
CEA <4.5 1.02 0.49–2.12 2.15 1.08–4.29 1.89 0.91–3.91 0.086
Bilirubin 1.07 0.75–1.54 0.66 0.39–1.11
Past history
Chronic pancreatitis 1.78 0.32–10.14 2.41 0.47–12.35
Diabetes mellitus 1.27 0.62–2.63 1.72 0.89–3.31
Medication history
Aspirin 1.78 0.32–10.14 1.17 0.21–6.60
Metformin 1.17 0.58–2.35 1.29 0.63–2.63
Statin 4.79 1.71–13.40 4.69 1.41–15.6 0.012 3.86 1.38–10.78 4.11 1.28–13.2 0.017
LN, lymph node; CA, carbohydrate antigen; CEA, carcinoembryonic antigen; OR, odds ratio; CI, confidence interval.
*Factors for CR or PR at two cycles of chemotherapy, †Factors for a tumor stabilization effect (CR, PR, or SD) by six cycles of chemotherapy.
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Statistical analysis to determine “long-term response” 
factors
We used univariate and multivariate analyses to determine fac-
tors associated with “long-term response.” Four different fac-
tors had an effect on “long-term response” in univariate anal-
ysis (Table 2). These included locally advanced stage (OR, 2.71; 
95% CI, 1.13–6.51; p=0.025), liver metastasis (OR, 0.46; 95% CI, 
0.24–0.89; p=0.023), history of statin treatment (OR, 3.86; 95% 
CI, 1.38–10.78; p=0.01), and CEA level <4.5 ng/mL (OR, 2.15; 
95% CI, 1.08–4.29; p=0.029). Multivariate analysis identified 
only one clinical feature that may affect “long-term response”: 
a history of statin treatment, which was an independent favor-
able factor (OR, 4.11; 95% CI, 1.28–13.2; p=0.017).
Prognostic factors for survival
According to the Cox hazards regression model, liver metastasis 
was a prognostic factor that significantly affected OS (HR, 1.78; 
95% CI, 1.05–3.01; p=0.031) and PFS (HR, 1.55; 95% CI, 1.09–
2.19; p=0.013) (Table 3). A history of statin treatment, which was 
Table 3. Prognosis Factor Analysis
Clinical factors
OS PFS
HR 95% CI p value HR 95% CI p value
Tumor size & location
Tumor size 1.05 0.93–1.17 0.390 1.08 0.96–1.20 0.169
Head 0.91 0.65–1.25 0.554 1.06 0.78–1.43 0.705
Body 0.85 0.59–1.21 0.374 0.86 0.62–1.21 0.399
Tail 1.31 0.93–1.84 0.112 1.07 0.78–1.48 0.655
Number of metastatic organs
0 (locally advanced) 0.76 0.48–1.21 0.261 0.685 0.44–1.05 0.088
1 1.02 0.74–1.41 0.869 1.1 0.81–1.48 0.521
≥2 1.13 0.81–1.58 0.46 1.13 0.82–1.55 0.442
Site of metastasis
Liver metastasis 1.78 1.05–3.01 0.031 1.55 1.09–2.19 0.013
Lung metastasis 1.56 0.85–2.87 0.148 1.18 0.65–2.14 0.576
Carcinomatosis 1.09 0.53–2.24 0.810 0.71 0.33–1.50 0.367
Bone metastasis 1.28 0.43–3.80 0.648 1.02 0.33–3.12 0.965
LN metastasis
Regional LN 1.31 0.92–1.86 0.131 0.96 0.67–1.37 0.815
Distant LN 0.62 0.33–1.17 0.147 0.62 0.33–1.16 0.135
Lab parameters
CA 19-9 <1000 0.81 0.56–1.16 0.246 0.88 0.61–1.26 0.497
CEA <4.5 0.95 0.65–1.37 0.793 0.99 0.72–1.35 0.972
Bilirubin 1.01 0.57–1.81 0.956 1.03 0.58–1.83 0.913
Past history
Chronic pancreatitis 1.18 0.45–3.13 0.729 0.68 0.26–1.82 0.452
Diabetes mellitus 0.81 0.45–1.45 0.486 0.78 0.44–1.41 0.423
Medication history
Aspirin 0.57 0.18–1.78 0.338 0.48 0.16–1.43 0.191
Metformin 0.86 0.46–1.62 0.647 1.04 0.54–1.99 0.891
Statin 0.48 0.26–0.92 0.026 0.55 0.31–1.01 0.052
LN, lymph node; CA, carbohydrate antigen; CEA, carcinoembryonic antigen; OS, overall survival; HR, hazard ratio; CI, confidence interval; PFS, progression-free 
survival.
Fig. 1. A history of statin treatment was revealed to be the only favorable 
factor associated with “long-term response” on multivariate analysis and 
with OS. Kaplan-Meier curves for overall survival in pancreatic cancer pa-
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revealed to be the only favorable factor associated with “long-
term response,” was also significantly associated with OS after 
adjusting for all potential confounders (HR, 0.48; 95% CI, 0.26–
0.92; p=0.026) (Fig. 1, Table 3).
DISCUSSION
Pancreatic cancer has a poor outcome, with a 5-year survival 
rate of only 5%.1-3 There have been significant medical advanc-
es, including targeted agents for unresectable advanced pan-
creatic cancer; however, the median survival time is approxi-
mately 6 months after the standard chemotherapy regimen of 
gemcitabine combined with erlotinib.6 Because of this very poor 
prognosis, a favorable response in the early chemotherapy cy-
cles is important for longer survival times.
In this study, statins in combination with erlotinib and gem-
citabine chemotherapy were associated with a good response 
in advanced pancreatic cancer for both short- and long-term 
chemotherapy. It is notable that concomitant use of statins 
showed a positive, long-term effect after >6 cycles of gemcita-
bine-erlotinib treatment. Considering that the median surviv-
al time of patients with advanced pancreatic cancer was ap-
proximately 6 months, the use of statins as chemoadjuvant 
treatment was meaningful in that it maintained tumor stabili-
zation for the median survival time, assuming that the duration 
of one cycle of chemotherapy was equivalent to 1 month.
Many clinical studies have evaluated the potential anti-can-
cer effects of additional statin treatment. Colon cancer has been 
widely studied for associations between statin use and cancer 
incidence.19-24 The protective effect of statins against the devel-
opment of pancreatic cancer has also been presented.25 Khura-
na, et al.25 reported that statin administration for >6 months 
was associated with a reduced risk of pancreatic cancer by 67%. 
Statins are 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-
CoA) reductase inhibitors that reduce the synthesis of intra-
cellular cholesterol by reversible inhibition of the conversion 
of HMG-CoA to mevalonate in the mevalonate pathway.26 This 
pathway also produces farnesyl pyrophosphate and geranyl-
geranyl pyrophosphate, both of which are involved in the post-
translational modification of cellular proteins including the 
Ras, Rab, Rac, and Rho families, which in turn influence cell 
proliferation, cell motility, and posttranslational modifica-
tion.27,28 Statins block this pathway downstream, which may re-
sult in anti-cancer activity due to inhibition of tumor growth, 
angiogenesis, and metastasis.12,14-16,29
Hong, et al.30 reported the first human clinical trial with 
statins used in combination with standard gemcitabine che-
motherapy for advanced pancreatic cancer. This study showed 
that adding low-dose simvastatin to gemcitabine does not pro-
vide any clinical benefit when compared with gemcitabine plus 
a placebo.
However, we need to consider the potential synergic effect of 
statins and erlotinib referred to in many studies. By depleting 
mevalonate metabolites such as dolichol, farnesyl, and geranyl-
geranyl pyrophosphate through the inhibition of HMG-CoA 
reductase, statins have the potential to inhibit both epidermal 
growth factor receptor (EGFR) and its downstream signaling 
cascades.31-33 Mantha, et al.34 reported that a combination of lo-
vastatin and gefitinib, an anti-EGFR agent, showed significant 
synergistic anti-cancerous effects and enhanced EGFR inhibi-
tion.
Approximately 70–90% of pancreatic cancer patients are 
thought to have the v-Ki-ras2 Kirsten rat sarcoma viral onco-
gene homolog (KRAS).35 It is known that KRAS mutations are 
associated with a worse prognosis after anti-EGFR-targeted 
therapy in lung and colorectal cancer. It has been reported that 
statins may overcome resistance to anti-EGFR-targeted agents 
in colon cancer cells with the KRAS mutation.36 Our study also 
demonstrated that statins in combination with erlotinib were 
positively associated with a “long-term response.” Therefore, 
statins may be a potential chemoadjuvant therapy along with 
anti-EGFR treatment for advanced pancreatic cancer patients 
with KRAS mutations.
In summary, this study suggests that statins have a favorable 
effect on the response to gemcitabine and erlotinib chemother-
apy in advanced pancreatic cancer after six cycles of chemo-
therapy. As the median survival time of patients with advanced 
pancreatic cancer was approximately 6 months, statins may 
have a significant role as chemoadjuvant therapy for stabiliz-
ing long-term tumor growth. It is also important to note that 
statins have been used for a long time in cardiovascular disease 
with a proven safety record. Furthermore, prospective studies 
are needed to evaluate the efficacy of statins combined with 
chemotherapy containing anti-EGFR-targeted agents to over-
come resistance to this treatment in advanced pancreatic can-
cer with KRAS mutations.
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